Cargando…
Driving β(2)- While Suppressing α-Adrenergic Receptor Activity Suppresses Joint Pathology in Inflammatory Arthritis
OBJECTIVE: Hypersympathetic activity is prominent in rheumatoid arthritis, and major life stressors precede onset in ~80% of patients. These findings and others support a link between stress, the sympathetic nervous system and disease onset and progression. Here, we extend previous research by evalu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249812/ https://www.ncbi.nlm.nih.gov/pubmed/34220796 http://dx.doi.org/10.3389/fimmu.2021.628065 |
_version_ | 1783716977498390528 |
---|---|
author | Bellinger, Denise L. Wood, Carlo Wergedal, Jon E. Lorton, Dianne |
author_facet | Bellinger, Denise L. Wood, Carlo Wergedal, Jon E. Lorton, Dianne |
author_sort | Bellinger, Denise L. |
collection | PubMed |
description | OBJECTIVE: Hypersympathetic activity is prominent in rheumatoid arthritis, and major life stressors precede onset in ~80% of patients. These findings and others support a link between stress, the sympathetic nervous system and disease onset and progression. Here, we extend previous research by evaluating how selective peripherally acting α/β(2)-adrenergic drugs affect joint destruction in adjuvant-induced arthritis. METHODS: Complete Freund’s adjuvant induced inflammatory arthritis in male Lewis rats. Controls received no treatment. Arthritic rats then received vehicle or twice-daily treatment with the α-adrenergic antagonist, phentolamine (0.5 mg/day) and the β(2)-adrenergic agonist, terbutaline (1200 µg/day, collectively named SH1293) from day (D) of disease onset (D12) through acute (D21) and severe disease (D28). Disease progression was assessed in the hind limbs using dorsoplantar widths, X-ray analysis, micro-computed tomography, and routine histology on D14, D21, and D28 post-immunization. RESULTS: On D21, SH1293 significantly attenuated arthritis in the hind limbs, based on reduced lymphocytic infiltration, preservation of cartilage, and bone volume. Pannus formation and sympathetic nerve loss were not affected by SH1293. Bone area and osteoclast number revealed high- and low-treatment-responding groups. In high-responding rats, treatment with SH1293 significantly preserved bone area and decreased osteoclast number, data that correlated with drug-mediated joint preservation. SH1293 suppressed abnormal bone formation based on reduced production of osteophytes. On D28, the arthritic sparing effects of SH1293 on lymphocytic infiltration, cartilage and bone sparing were maintained at the expense of bone marrow adipocity. However, sympathetic nerves were retracted from the talocrural joint. CONCLUSION AND SIGNIFICANCE: Our findings support a significant delay in early arthritis progression by treatment with SH1293. Targeting sympathetic neurotransmission may provide a strategy to slow disease progression. |
format | Online Article Text |
id | pubmed-8249812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82498122021-07-03 Driving β(2)- While Suppressing α-Adrenergic Receptor Activity Suppresses Joint Pathology in Inflammatory Arthritis Bellinger, Denise L. Wood, Carlo Wergedal, Jon E. Lorton, Dianne Front Immunol Immunology OBJECTIVE: Hypersympathetic activity is prominent in rheumatoid arthritis, and major life stressors precede onset in ~80% of patients. These findings and others support a link between stress, the sympathetic nervous system and disease onset and progression. Here, we extend previous research by evaluating how selective peripherally acting α/β(2)-adrenergic drugs affect joint destruction in adjuvant-induced arthritis. METHODS: Complete Freund’s adjuvant induced inflammatory arthritis in male Lewis rats. Controls received no treatment. Arthritic rats then received vehicle or twice-daily treatment with the α-adrenergic antagonist, phentolamine (0.5 mg/day) and the β(2)-adrenergic agonist, terbutaline (1200 µg/day, collectively named SH1293) from day (D) of disease onset (D12) through acute (D21) and severe disease (D28). Disease progression was assessed in the hind limbs using dorsoplantar widths, X-ray analysis, micro-computed tomography, and routine histology on D14, D21, and D28 post-immunization. RESULTS: On D21, SH1293 significantly attenuated arthritis in the hind limbs, based on reduced lymphocytic infiltration, preservation of cartilage, and bone volume. Pannus formation and sympathetic nerve loss were not affected by SH1293. Bone area and osteoclast number revealed high- and low-treatment-responding groups. In high-responding rats, treatment with SH1293 significantly preserved bone area and decreased osteoclast number, data that correlated with drug-mediated joint preservation. SH1293 suppressed abnormal bone formation based on reduced production of osteophytes. On D28, the arthritic sparing effects of SH1293 on lymphocytic infiltration, cartilage and bone sparing were maintained at the expense of bone marrow adipocity. However, sympathetic nerves were retracted from the talocrural joint. CONCLUSION AND SIGNIFICANCE: Our findings support a significant delay in early arthritis progression by treatment with SH1293. Targeting sympathetic neurotransmission may provide a strategy to slow disease progression. Frontiers Media S.A. 2021-06-17 /pmc/articles/PMC8249812/ /pubmed/34220796 http://dx.doi.org/10.3389/fimmu.2021.628065 Text en Copyright © 2021 Bellinger, Wood, Wergedal and Lorton https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Bellinger, Denise L. Wood, Carlo Wergedal, Jon E. Lorton, Dianne Driving β(2)- While Suppressing α-Adrenergic Receptor Activity Suppresses Joint Pathology in Inflammatory Arthritis |
title | Driving β(2)- While Suppressing α-Adrenergic Receptor Activity Suppresses Joint Pathology in Inflammatory Arthritis |
title_full | Driving β(2)- While Suppressing α-Adrenergic Receptor Activity Suppresses Joint Pathology in Inflammatory Arthritis |
title_fullStr | Driving β(2)- While Suppressing α-Adrenergic Receptor Activity Suppresses Joint Pathology in Inflammatory Arthritis |
title_full_unstemmed | Driving β(2)- While Suppressing α-Adrenergic Receptor Activity Suppresses Joint Pathology in Inflammatory Arthritis |
title_short | Driving β(2)- While Suppressing α-Adrenergic Receptor Activity Suppresses Joint Pathology in Inflammatory Arthritis |
title_sort | driving β(2)- while suppressing α-adrenergic receptor activity suppresses joint pathology in inflammatory arthritis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249812/ https://www.ncbi.nlm.nih.gov/pubmed/34220796 http://dx.doi.org/10.3389/fimmu.2021.628065 |
work_keys_str_mv | AT bellingerdenisel drivingb2whilesuppressingaadrenergicreceptoractivitysuppressesjointpathologyininflammatoryarthritis AT woodcarlo drivingb2whilesuppressingaadrenergicreceptoractivitysuppressesjointpathologyininflammatoryarthritis AT wergedaljone drivingb2whilesuppressingaadrenergicreceptoractivitysuppressesjointpathologyininflammatoryarthritis AT lortondianne drivingb2whilesuppressingaadrenergicreceptoractivitysuppressesjointpathologyininflammatoryarthritis |